Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07236606 · ClinicalTrials.gov registry record · Phase 3
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
A Phase 3 study, sponsored by REGENXBIO.
- Active
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT07236606 is a Phase 3 study that is active but no longer recruiting, run by REGENXBIO. The registered enrollment target is 2 participants.
The verdict
NCT07236606, a Phase 3 study, is active but no longer recruiting, sponsored by REGENXBIO.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety, efficacy, and pharmacodynamic dose ranging study to determine whether RGX-121 is safe, effective and well-tolerated by patients with MPS II (Hunter Syndrome)
Interventions
- GENETIC RGX-121-3102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2025-11-25 |
| Est. Completion | 2031-05-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07236606
The ClinicalTrials.gov registry entry for NCT07236606 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is REGENXBIO, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RGX-121-3102 is the first listed.
NCT07236606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07236606 about?
NCT07236606 is a clinical study titled "RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)". RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety, efficacy, and pharmacodynamic dose ranging study to determine whether RGX-121 is safe, effective and well-tolerated by patients with...
What is the current status of trial NCT07236606?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2025-11-25. Estimated completion is 2031-05-30.
What interventions are being tested in trial NCT07236606?
The interventions under investigation include: RGX-121-3102 (GENETIC).
Who is sponsoring clinical trial NCT07236606?
This trial is sponsored by REGENXBIO, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.